Technical Analysis for ADMS - Adamas Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 6.28 -1.88% -0.12
ADMS closed down 1.88 percent on Thursday, April 18, 2019, on 44 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ADMS trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
NR7 Range Contraction 0.00%
Stochastic Reached Oversold Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish -1.88%
Oversold Stochastic Weakness -1.88%
Slingshot Bearish Bearish Swing Setup -4.56%
Oversold Stochastic Weakness -4.56%
New 52 Week Closing Low Bearish -2.33%
Hammer Candlestick Bullish -2.33%

Older signals for ADMS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Adamas Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics for chronic disorders of the central nervous systems (CNS) in the United States. The company is developing its lead product candidate, ADS-5102 that has completed a Phase 2/3 clinical study for levodopa induced dyskinesia, a complication of Parkinson's disease; and as a treatment for chronic behavioral symptoms associated with traumatic brain injury. It is also developing ADS-8800 and ADS-9000 series of products for use in a range of CNS indications; ADS-8704, a fixed-dose combination of memantine and donepezil for the treatment of moderate to severe dementia related to alzheimer's disease; and ADS-8902, a triple combination antiviral drug therapy for influenza. In addition, the company develops memantine-based therapeutics portfolio includes Namenda XR and MDX-8704, which are used in the treatment of dementia associated with moderate to severe alzheimer's disease. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
Chemical Compounds Alzheimer's Disease Influenza Parkinson's Disease Psychiatry Psychiatric Diagnosis Dementia Treatment Of Alzheimer's Disease Cognitive Disorders Drug Therapy Chronic Disorders Learning Disabilities Traumatic Brain Injury
Is ADMS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 32.9
52 Week Low 6.2152
Average Volume 611,270
200-Day Moving Average 14.5754
50-Day Moving Average 8.3556
20-Day Moving Average 6.8865
10-Day Moving Average 6.568
Average True Range 0.3446
ADX 34.12
+DI 14.2093
-DI 32.4627
Chandelier Exit (Long, 3 ATRs ) 7.2162
Chandelier Exit (Short, 3 ATRs ) 7.249
Upper Bollinger Band 7.6392
Lower Bollinger Band 6.1338
Percent B (%b) 0.1
BandWidth 21.860161
MACD Line -0.515
MACD Signal Line -0.54
MACD Histogram 0.0251
Fundamentals Value
Market Cap 141.39 Million
Num Shares 22.5 Million
EPS -2.99
Price-to-Earnings (P/E) Ratio -2.10
Price-to-Sales 2373.51
Price-to-Book 4.03
PEG Ratio -0.06
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.66
Resistance 3 (R3) 6.69 6.60 6.59
Resistance 2 (R2) 6.60 6.50 6.58 6.57
Resistance 1 (R1) 6.44 6.45 6.40 6.41 6.55
Pivot Point 6.35 6.35 6.33 6.33 6.35
Support 1 (S1) 6.19 6.25 6.15 6.16 6.01
Support 2 (S2) 6.10 6.20 6.08 5.99
Support 3 (S3) 5.94 6.10 5.97
Support 4 (S4) 5.91